Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$70.11 USD
-1.30 (-1.82%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $70.20 +0.09 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.11 USD
-1.30 (-1.82%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $70.20 +0.09 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -33.98% and 82.48%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
by Zacks Equity Research
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
by Zacks Equity Research
Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
by Zacks Equity Research
Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
by Zacks Equity Research
Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
by Zacks Equity Research
Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
by Ekta Bagri
Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
Company News for Dec 28, 2023
by Zacks Equity Research
Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -87.50% and 98.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Cytokinetics (CYTK) Could Rally 75.5%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Cytokinetics (CYTK) points to a 75.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs
by Zacks Equity Research
Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.
Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cytokinetics (CYTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -8.94% and 65.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Cytokinetics (CYTK) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 62.8% upside potential for Cytokinetics (CYTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Dips 20% so Far in 2023 on Setbacks
by Zacks Equity Research
Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -18.85% and 73.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback
by Zacks Equity Research
Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.
Is a Surprise Coming for Cytokinetics (CYTK) This Earnings Season?
by Zacks Equity Research
Cytokinetics (CYTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates
by Ekta Bagri
We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.